Kyowa Kirin Co., Ltd. (4151) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyowa Kirin Co., Ltd. (4151:JPX), powered by AI.

Current Price
¥2,388.5
P/E Ratio
18.6
Market Cap
1.3T
Sector
Healthcare
What is the Kyowa Kirin Co., Ltd. stock price forecast?

Kyowa Kirin Co., Ltd. is currently trading at ¥2,388.5. View real-time AI analysis on Alpha Lenz.

What is Kyowa Kirin Co., Ltd. insider trading activity?

View the latest insider trading data for Kyowa Kirin Co., Ltd. on Alpha Lenz.

What is Kyowa Kirin Co., Ltd.'s P/E ratio?

Kyowa Kirin Co., Ltd.'s P/E ratio is 18.6.

Kyowa Kirin Co., Ltd.

JPX · 4151
¥2,389-12(-0.50%)Market closedJPX regular session 09:00–15:00 JST
Ask about Kyowa Kirin Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Kyowa Kirin Co., Ltd. trades at a P/E of 18.6 (fair value) with modest ROE of 7.7%. Operating margin of 20.6% indicates strong profitability.

Ask for details

Company Overview

Kyowa Kirin Co., Ltd. is a prominent pharmaceutical company based in Japan, specializing in the research, development, and marketing of pharmaceuticals, biotechnology products, and medical devices. Its primary function revolves around creating innovative solutions for unmet medical needs, with a specific focus on therapeutic areas such as oncology, nephrology, immunology, and the central nervous system. Kyowa Kirin's commitment to research and development is underscored by significant investments in cutting-edge biotechnology and partnerships that foster scientific advancements. The company's contribution extends to providing effective healthcare solutions globally, impacting various industries including healthcare, pharmaceuticals, and biotechnology. As a leading player in the pharmaceutical sector, Kyowa Kirin plays a crucial role in advancing medical science and improving patient outcomes through its diverse product offerings and ongoing clinical trials. This makes it an influential entity within Japan's pharmaceutical industry and the global market at large, continuing to drive innovation and therapeutic discoveries.

CEOMr. Masashi Miyamoto Ph.D.
SectorHealthcare
IndustryDrug Manufacturers - General
Employees5,669

Company Statistics

FY 2025

Profile

¥1,250,264,151,377Market Cap
¥496,826,000,000Revenue
0.00Shares Out
5,669Employees

Margins

74.25%Gross
23.55%EBITDA
20.59%Operating
17.56%Pre-Tax
13.49%Net

Valuation

18.65P/E
1.40P/B
2.52EV/Sales
8.82EV/EBITDA
231.53P/FCF

Growth (CAGR)

7.64%Rev 3Yr
9.31%Rev 5Yr
7.48%Op Inc 3Yr
11.63%Op Inc 5Yr
7.76%Net Inc 3Yr
7.35%Net Inc 5Yr

Returns

6.16%ROA
7.69%ROE
8.35%ROIC

Financial Health

¥218,769,000,000Cash & Cash Equivalents
¥-4,241,000,000Net Debt
24.01%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kyowa Kirin Co., Ltd. (ticker: 4151) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 5,669 employees. Market cap is $1.3T.

The current price is 2,388.5 with a P/E ratio of 18.65x and P/B of 1.4x.

ROE is 7.69% and operating margin is 20.59%. Annual revenue is $496.8B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kyowa Kirin Co., Ltd. (4151) Stock Forecast 2026 ¥2,388.5 — Price, Financials & Analyst Targets | Alpha Lenz